TMS

BlueGrace Acquires Evos Smart ToolsTM Optimization Platform

Retrieved on: 
Wednesday, March 6, 2024
Acquisition, TMS, Senior, Algorithm, API, Evos, Growth, Root cause analysis, Third-party logistics, Software as a service, BlueGrace Logistics, Video game

Tampa, FL, March 06, 2024 (GLOBE NEWSWIRE) -- BlueGrace Logistics , one of the largest Third-Party Logistics (3PL) providers in North America, today announced the acquisition of Evos Smart Tools, a SaaS optimization platform that helps shippers maximize resources and reduce costs through advanced supply chain algorithms and real-time data analytics.

Key Points: 
  • Tampa, FL, March 06, 2024 (GLOBE NEWSWIRE) -- BlueGrace Logistics , one of the largest Third-Party Logistics (3PL) providers in North America, today announced the acquisition of Evos Smart Tools, a SaaS optimization platform that helps shippers maximize resources and reduce costs through advanced supply chain algorithms and real-time data analytics.
  • “I’m thrilled to have Evos as part of the BlueGrace family,” said Bobby Harris, BlueGrace Founder and CEO.
  • Evos Smart Tools offers advanced order optimization algorithms based on customized business rules, configurable variables, and API connections to create load plans that align with unique customer requirements.
  • BlueGrace said it plans to enhance their existing BlueShip® platform by integrating Evos for real-time optimization and will continue to sell the SaaS platform as a standalone product.

Transportation Management System Market to cross $26.7 billion by 2032, Says Global Market Insights Inc.

Retrieved on: 
Wednesday, March 6, 2024
TMS, Atmosphere, USD, AI, SAP, Transport, Transportation management system, Internet of things, ITMS, Communication, Risk, Maersk, EU ETS, Cloud computing, App Store (iOS/iPadOS)

The transportation management system market valuation is predicted to reach USD 26.7 billion by 2032, as reported in a research study by Global Market Insights Inc.

Key Points: 
  • The transportation management system market valuation is predicted to reach USD 26.7 billion by 2032, as reported in a research study by Global Market Insights Inc.
  • Furthermore, the emergence of mobile applications and digital platforms enabling seamless communication and collaboration among stakeholders will favor the transportation management system market outlook.
  • Europe transportation management system market share is touted to surge at a rapid pace till 2032, attributed to stringent regulatory requirements and a focus on sustainability.
  • The major companies in transportation management system market are Infor, Generix Group, CH Robinson, Oracle, Descartes, Manhattan Associates, Wise Tech Global, SAP, Worldwide Express, E2open, and Trimble.

BrainsWay Reports Fourth Quarter and Full-Year 2023 Financial Results and Operational Highlights

Retrieved on: 
Wednesday, March 6, 2024
TMS, Parkinson's disease, Medicine, Mental health, Human, Traction, Growth, Stroke, Adjustment, Safety, DSM-IV codes, Tic disorder, Mixed anxiety–depressive disorder, Brainsway, Journal, Rehabilitation, Science, OCD, Transcranial magnetic stimulation

BURLINGTON, Mass. and JERUSALEM, March 06, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a world leader in advanced and non-invasive treatment for brain disorders, today reported fourth quarter and full-year 2023 financial results and provided an operational update.

Key Points: 
  • and JERUSALEM, March 06, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a world leader in advanced and non-invasive treatment for brain disorders, today reported fourth quarter and full-year 2023 financial results and provided an operational update.
  • Gross margin for the fourth quarter of 2023 was 75%, an increase from 71% in the fourth quarter of 2022, and an increase from 74% in the third quarter of 2023.
  • Net income for the fourth quarter of 2023 was $0.1 million, compared to a net loss of $3.9 million for the fourth quarter of 2022, and a loss of $0.2 million for the third quarter of 2023.
  • Adjusted EBITDA1 for the fourth quarter of 2023 was approximately $0.8 million, compared to a loss of $3.6 million for the fourth quarter of 2022, and positive Adjusted EBITDA1 of $0.3 million in the third quarter of 2023.

Neuronetics Reports Record Fourth Quarter and Record Full Year 2023 Financial and Operating Results

Retrieved on: 
Tuesday, March 5, 2024
Social media, TMS, Transcranial magnetic stimulation, Telephone, Marketing, SSM Health, Webcast, Health, Neuronetics, Patient, Policy, Ferdinand Magellan, Knowledge, Psychotherapy

For the period ended December 31, 2023 and 2022, the Company shipped 205 and 213 systems, respectively.

Key Points: 
  • For the period ended December 31, 2023 and 2022, the Company shipped 205 and 213 systems, respectively.
  • Gross margin for the full year 2023 were 72.5%, a decrease of approximately 380 basis points from the full year 2022 gross margin of 76.3%.
  • Operating expenses during the full year 2023 was $82.3 million, a decrease of $2.5 million, or 2.9% compared to $84.8 million in the full year 2022.
  • See the accompanying financial table that reconciles EBITDA, which is a non-GAAP financial measure, to net loss.

PortPro Launches New Carrier and Brokerage TMS Solutions for Drayage Industry

Retrieved on: 
Tuesday, March 5, 2024
TMS, LOS, Broker, Carrier, Transport, Growth, Government, AB5

JERSEY CITY, N.J. and LOS ANGELES, March 05, 2024 (GLOBE NEWSWIRE) -- PortPro , the premier transportation software provider for the drayage industry, today announced the launch of two new TMS solutions designed exclusively for their client’s unique challenges.

Key Points: 
  • JERSEY CITY, N.J. and LOS ANGELES, March 05, 2024 (GLOBE NEWSWIRE) -- PortPro , the premier transportation software provider for the drayage industry, today announced the launch of two new TMS solutions designed exclusively for their client’s unique challenges.
  • The two new platforms include:
    PortPro for Carriers and Brokers - An all-in-one transportation management system built for drayage trucking companies operating both assets and a brokerage.
  • PortPro for Drayage Brokers — A web-based operating system designed and built exclusively for non-asset-based drayage brokerages who broker loads to different drayage trucking companies.
  • “For businesses like ours who have assets and a brokerage, it’s a game-changer,” said Philip Li, founder and CEO of DILE Solutions.

IntelliTrans: Revolutionizing Risk Management - The Power of Single Point of Control TMS

Retrieved on: 
Tuesday, March 5, 2024
Transport, TMS, Organization, Bols, Risk, Risk management

IntelliTrans , a leader in global multimodal transportation management solutions, discusses the pivotal role of transportation management systems in bolstering supply chain resilience through comprehensive risk management strategies centralized around a single point of control.

Key Points: 
  • IntelliTrans , a leader in global multimodal transportation management solutions, discusses the pivotal role of transportation management systems in bolstering supply chain resilience through comprehensive risk management strategies centralized around a single point of control.
  • The IntelliTrans TMS exemplifies this approach, granting clients comprehensive insight into inventory movements across multiple transportation modes and warehouses.
  • Having visibility ensures precise tracking of product locations throughout the transportation process and enables proactive inventory management to mitigate the risk of stockouts."
  • The IntelliTrans Transportation Management System (TMS) seamlessly integrates and unifies data from suppliers, carriers, and logistics partners.

Telix to Acquire ARTMS, Inc. and its Advanced Isotope Production Platform

Retrieved on: 
Monday, March 4, 2024
Acquisition, Pharmacy, TMS, TRIUMF, Actinium-225, Chemistry, Isotope, Sale, TLX, Physics, ASX, Clinical trial, Science, Ultra, Research, Partnership, Medical imaging

MELBOURNE, Australia, March 05, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has entered into an agreement to acquire radioisotope production technology firm ARTMS Inc. (ARTMS), its advanced cyclotron-based isotope production platform, manufacturing plant and stockpile of ultra-pure rare metals required for consumable target production.

Key Points: 
  • MELBOURNE, Australia, March 05, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has entered into an agreement to acquire radioisotope production technology firm ARTMS Inc. (ARTMS), its advanced cyclotron-based isotope production platform, manufacturing plant and stockpile of ultra-pure rare metals required for consumable target production.
  • Telix is currently validating multiple production locations of large-scale 89Zr production in the United States (U.S.) using the QIS system and select manufacturing and pharmacy partners.
  • ARTMS and Telix have been collaborating since 20202 to evaluate the potential of higher curie-scale (Ci) production of Illuccix®.
  • As part of the acquisition, Telix will also acquire the benefit of ARTMS’s production facility and clean rooms, located in Burnaby, BC (Canada).

EDAP Announces FDA Breakthrough Device Designation for Focal One® in the Treatment of Deep Infiltrating Rectal Endometriosis

Retrieved on: 
Monday, March 4, 2024
TMS, Woman, Diarrhea, FDA, Quality of life, Tenesmus, Food, DIE, Endometriosis, Quality, Constipation, Dyspareunia, Rectum, Prostate, Fatigue, EDAP, Patient, Diagnosis, MRI, Weakness, Pharmaceutical industry

“This designation reflects the FDA’s recognition that deep infiltrating endometriosis remains a significant unmet medical need in women’s health with few treatment alternatives.

Key Points: 
  • “This designation reflects the FDA’s recognition that deep infiltrating endometriosis remains a significant unmet medical need in women’s health with few treatment alternatives.
  • The Focal One system being granted a Breakthrough Device designation underscores the significance of this innovative development for DIE patients.
  • In January 2022, EDAP reported positive results from the Phase 2 Endo-HIFU-1R study (N=60) evaluating Focal One HIFU for the treatment of deep infiltrating rectal endometriosis, and this data was included in EDAP’s submission in consideration for receiving Breakthrough Device designation from the FDA.
  • In February 2024, EDAP announced the completion of enrollment in a Phase 3 study evaluating Focal One HIFU therapy for the treatment of deep infiltrating rectal endometriosis.

EDAP Announces Record Preliminary Fourth Quarter and Full-Year 2023 Revenues

Retrieved on: 
Thursday, February 29, 2024
Urology, TMS, Growth, EUR, EDAP, Prostate cancer

Record full-year 2023 preliminary unaudited revenue of EUR 60.4 million ($65.4 million USD), an increase of 9.6% over full-year 2022, driven by 31.7% HIFU growth

Key Points: 
  • Record full-year 2023 preliminary unaudited revenue of EUR 60.4 million ($65.4 million USD), an increase of 9.6% over full-year 2022, driven by 31.7% HIFU growth
    Record Q4 2023 preliminary unaudited revenue of EUR 19.6 million ($21.3 million USD), an increase of 24.8% over for Q4 2022, driven by 38.8% HIFU growth
    LYON, France, February 29, 2024 - EDAP TMS SA (Nasdaq: EDAP), a global leader in robotic energy-based therapies, today announced preliminary unaudited fourth quarter and full-year 2023 revenues.
  • “Our fourth quarter and full-year 2023 revenues each hit record levels driven by increased demand for Focal One Robotic HIFU and solid execution from our capital sales and regional clinical teams,” said Ryan Rhodes, Chief Executive Officer of EDAP TMS.
  • “During the fourth quarter, we saw growing demand for Focal One from both leading academic and community hospitals across global markets.
  • EDAP expects to release final Fourth quarter and Full-year financial results in March.

uniQure Announces 2023 Financial Results and Highlights Recent Company Progress

Retrieved on: 
Wednesday, February 28, 2024
Acquisition, Fabry disease, TMS, Natural history, CSL Behring, ALS, Research, FDA, Partnership, Cerebrospinal fluid, Food, CSL, Etranacogene dezaparvovec, Sale, TFC, Conference, SOD1, Unified, Information technology, AFL, Immunosuppression, Patient, Disease, Phase, Hand, IND, CGMP, State, Temporal lobe epilepsy, Pharmaceutical industry

LEXINGTON, Mass. and AMSTERDAM, Feb. 28, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the fourth quarter and full year 2023 and highlighted recent progress across its business.

Key Points: 
  • and AMSTERDAM, Feb. 28, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the fourth quarter and full year 2023 and highlighted recent progress across its business.
  • “We are pleased with the progress made across the company in 2023 and are now laser-focused on execution across multiple clinical programs,” stated Matt Kapusta, chief executive officer of uniQure .
  • By the end of 2024, the Company expects to have greater clarity regarding a potential approval pathway for AMT-130.
  • AMT-191 for the treatment of Fabry disease – In November 2023, the Company announced the clearance of an IND for the Phase I/IIa clinical study of AMT-191.